Press "Enter" to skip to content

Gelesis, Maker Of Weight Loss Pill, Concludes SPAC Deal; Trading Kickstarts Today

PureTech Health plc (NASDAQ: PRTC) founded entity Gelesis Inc, maker of weight management aid, has completed its business combination with Capstar Special Purpose Acquisition Corp (NYSE: CPSR). 

  • The publicly-traded company will be Gelesis Holdings Inc and will begin trading on the New York Stock Exchange under the ticker symbol “GLS” from today.
  • Both Gelesis and Capstar shareholders voted to approve the business combination. The transaction generated approximately $105 million in gross proceeds, which will be mainly used to support the broad launch of Plenity.
  • Related: FDA-Approved Weight Loss Drug Plenity’s Parent Announces SPAC Deal: What Investors Should Know.
  • “We are pleased with the completion of this transaction, which now makes Gelesis the third publicly-traded Founded Entity for PureTech,” said Eric Elenko, Chief Innovation and Strategy Officer at PureTech. “
  • Plenity is FDA-cleared to aid in weight management in adults with excess weight or obesity, as defined by a Body Mass Index of 25 to 40 kg/m² when used in conjunction with diet and exercise. 
  • Plenity is designed to help people feel satisfied with smaller meal portions to eat less and lose weight.
  • It is taken orally as three capsules with 16 ounces of water twice a day, 20 minutes before lunch and dinner. 
  • A Plenity subscription costs $98 for a four-week supply ($1.75 per meal).
  • Price Action: CPSR shares closed higher by 9.85% at $7.36 on Thursday.

© 2022 Benzinga does not provide investment advice. All rights reserved.

This post was originally published on this site

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *